Overview
Directors
Codes of Conduct
|
|
 |
|
Professor Bryan RG Williams
Non-Executive Chairman
BSc. (Hons), PhD, Hon. FRSNZ
|
| |
Professor Bryan Williams was appointed Chairman of the Board of Directors in November 2006. He has been one of the Company's directors since March 2006 when he was appointed by the Company's Board to fill the vacancy created by the resignation of Professor David de Kretser from the Board of Directors. Professor Williams has over 30 years of experience in basic and pre-clinical cancer research. Since January 2006, he has been the director of the Monash Institute of Medical Research in Melbourne, Australia. From 1991 to 2005, Professor Williams was Chairman of the Department of Cancer Biology, Lerner Research Institute, The Cleveland Clinic Foundation, Cleveland, Ohio. From 1993 to 2005, he was Professor, Department of Genetics at Case Western Reserve University, Cleveland, Ohio. From 1998 to 2005, he was an Adjunct Professor in the Departments of Chemistry at Cleveland State University and Kent State University, also both in Ohio. Professor Williams holds a BSc. (Hons) (Microbiology) and PhD (Microbiology) from the University of Otago, New Zealand. He is an Honorary Fellow of the Royal Society of New Zealand. |
 |
|
Christopher Naughton
President and Chief Executive Officer
BEc, LLB
|
| |
Mr. Naughton has been President, Chief Executive Officer and director of the Company since the Company's inception in December 2000. He has been the Managing Director of Novogen since March 1997. Mr. Naughton was appointed Chairman of Glycotex in September 2005. He received degrees in Economics from the Australian National University and in Law from the University of New South Wales. He completed the Program for Management Development at the Harvard Business School and is admitted to practice as an attorney in New South Wales. After working in merchant banking, he has spent over 20 years in the pharmaceutical industry including appointments as a director of Wellcome Australia Limited and in world-wide business development with the Wellcome Foundation Limited in the UK. |
 |
|
Stephen Breckenridge
Non-Executive Director
M Tax, FCA, FTIA
|
| |
Mr. Breckenridge has been one of the Company's directors since August 2003. He has had over 25 years of experience in public practice as a chartered accountant in Australia and, since July 2004, has been the head of international transfer pricing for Australia and Asia at Baker & McKenzie (a global law firm) in Sydney. Mr. Breckenridge has been managing director of Breckenridge Consulting Pty Ltd since 2001, which provides independent tax and management advice to multi-nationals and small and medium enterprises, (SME's). Until 2001, he was a tax partner for 24 years with KPMG in Sydney where he provided corporate tax advice to a wide cross section of businesses in Australia and overseas with particular emphasis in later years on international transfer pricing. He has also been involved in the pharmaceutical and chemical industries over a long period including several industry association committees and leading industry focus groups within KPMG. From 2003 to 2004, Mr. Breckenridge was employed by Pitcher Partners Pty Ltd., an accounting firm in Sydney where he provided international tax advice to a broad range of businesses. He has been a member of the Australian Institute of Company Directors since May 2006. He holds a Master of Tax degree from the University of Sydney and is a fellow of the Institute of Chartered Accountants and the Tax Institute of Australia. |
 |
|
Philip A Johnston
Non-Executive Director
Dip Eng (Production)
|
| |
Mr. Johnston has been a director since April 2001. He has more than 25 years of experience in the pharmaceutical industry. He has been a non-executive director of Novogen Limited ("Novogen"), the Company's parent, since 1997 and chairman of Novogen since January 2001. Since June 2004, Mr. Johnston has been a non-executive director of LIPA Pharmaceuticals Limited. He is also the managing director of Qualcare Management Pty. Ltd. Mr. Johnston has been a director of Glycotex, Inc. ("Glycotex"), a subsidiary of Novogen, since September 2005. From June 1988 to September 1997, he was an executive director of Wellcome Australia Limited. He was previously a director of two subsidiary companies of GlaxoWellcome. He has had responsibility for production, distribution, quality assurance and consumer product development and has been directly involved in the establishment of strategic alliances and joint ventures. Mr. Johnston has completed a number of executive development programs including programs at the University of New South Wales and the London Business School. |
 |
|
Professor Paul J Nestel
Non-Executive Director
AO, MD, FTSE, FRACP, FAHA, FCSAND
|
| |
Professor Nestel has been a director since April 2001. He has been a non-executive director of Novogen since September 2001. Since January 1995, he has been senior principal research fellow and head of the cardiovascular nutrition laboratory at the Baker Medical Research Institute, Victoria. Professor Nestel has also been a consultant physician at the Alfred Hospital, Melbourne. He is president of the International Life Sciences Institute (Australasia) and is a member of the board of directors of ILSI South East Asia. He was formally a clinical professor in medicine at The Flinders University of South Australia. Professor Nestel is an Officer of the Order of Australia. |
 |
|
William D Rueckert
Non-Executive Director
|
| |
Mr. Rueckert is president and director of Rosow & Company, a private investment firm based in Connecticut since 1990 and is the Managing Member of Oyster Management Group LLC investment fund. Mr. Rueckert is a Director of Emergency Filtration Products, Inc. a public manufacturer and marketer of respiratory filtration devices and is a Director of Glycotex Inc an 83 per cent owned unlisted subsidiary of Novogen Limited. Prior to his current positions, Mr. Rueckert has been president and director of Eastern Capital Development, LLC since 1999, treasurer of Moore & Munger, Inc. a company with interests in the petroleum and resort development industries, from 1988 until 1990, and was president of United States Oil Company, a publicly traded oil exploration business, from 1981 to 1988. Among his many civic associations, Mr. Rueckert is director and president of the Cleveland H. Dodge Foundation, a private philanthropic organization in New York City and chairman of the Board of the Trustees of Teachers College, Columbia University. |
 |
|
David R Seaton
Company Secretary and CFO
BBus, MCom, CPA
|
| |
Mr. Seaton is the CFO of Novogen Limited. He holds a degree in Business Studies as well as a Master of Commerce degree from the University of New South Wales. He has completed management development programs at Northwestern University in Chicago as well as Duke University and the London Business School. He has over 16 years experience in the pharmaceutical industry and prior to joining Novogen in 1999 was the Finance Director of GlaxoWellcome Australia Limited. Mr Seaton was also Finance Director of Wellcome Australia Ltd before its merger with Glaxo in 1995. |
|
|
| Contact Details |
|
| |
Marshall Edwards, Inc.
140 Wicks Road
North Ryde NSW 2113
Australia
T: +61 2 8877 6196
F: +61 2 9878 8474
email  |
